Australian (ASX) Stock Market Forum

IHL - Incannex Healthcare

Jump to new
springhill

springhill

Make the drill work for YOU
Joined
20 June 2007
Posts
2,555
Reactions
11
MUM are a little gold spec that might (or might not?) be worth looking into.
Mount Magnet are exploring the Curara Well Gold Deposit and have recently concluded a 27 hole, 3327m RC drilling program.
Highlights included
16m @ 10.71g/t Au from 6m including 4m @ 34.17g/t Au from 8m
4m @ 2.59g/t Au from 10m
4m @ 8.18g/t Au from 46m
4m @ 6.6g/t Au from 85m
1m @ 9.55g/t Au from 63m

They also seem to have a plant that is under care and maintanence.

Current Share Price 4.9c
MC $7m
Shares on Issue 145m
High/Low 13c/4c
Cash at Hand $1.72m
Expenses this Quarter $350k
 
Re: MUM - Mount Magnet South NL

Agreed, it is interesting.

Based on the recent feasibility study there is value at the current market cap even in light of the costs coming through a little higher than expected. It is also worth noting that the subsequent resource upgrade was not factored into the FS. That said, given the cost of production one would expect another capital raising in the midst should they fail to secure non-equity financing, and this might weigh on the price post raising - but a run leading into the raising wouldn't be uncharacteristic of a speccy like this :xyxthumbs
 
On October 31st, 2016, Mount Magnet South Limited (MUM) changed its name and ASX code to Impression Healthcare Limited (IHL).
 
Impression Healthcare up 46.67% today to 2.2c on huge volume of almost 67 million shares after announcing that it has commenced the application process to obtain licences from the State Department of Health, Victoria and the Federal Office of Drug Control for the importation, storage, distribution and export of medicinal cannabis products.

The rest of the announcement went on to say:
The licenses being pursued will allow Impression, subject to individual product permit issue, the capacity to capitalise on local and international opportunities by importing and exporting a wide range of therapeutic cannabis products to generate cash flow. It is intended that imported products be saleable under the Special Access Schemes and Authorised Prescriber Network, as regulated under the Therapeutic Goods Administration. The procurement of an export license is consistent with the Company's strategy of progressive and selective international expansion, with sales of the Company's existing product, the Knight Guard, having commenced in New Zealand.

The application process is being completed in conjunction with the Company's cannabis consultants. And, Impression expects to have the license and additional security protocols in place at its Melbourne-based laboratory and manufacturing facility by the first quarter of 2019.
Click to expand...

Some more info here: https://smallcaps.com.au/impression-healthcare-prepares-medical-cannabis-market-launch/

While it's a positive announcement it's also a little short on detail. It's unsurprising that after reaching an intraday high of 3.7c it retreated back to 2.2c by the close. I wouldn't be jumping on board on this little taste of cannabis fever, but who knows how things may develop down the line? Further announcements may provide more detail of projected revenues etc.

big.chart-IHL.gif
 
Agree Greg …. big wide ranging bars indicate a bit of a P and D

Definitely wait for the dust to settle here:cautious:
 
Just coming back to IHL around five weeks after my last post. After trading mostly between 2c and 3c since 24 October, IHL slipped below 2c last week on low volume. However, today saw it jump back over 2c on solid volume of around 12 million shares, up 29.41% on Friday's close.

I have read elsewhere that IHL are expecting that the licenses applied for last month (i.e. the importation, storage, distribution and export of medicinal cannabis products) are expected to be granted early next year.

Those interested in licenses being granted in this area can refer to this page: https://www.odc.gov.au/summary-licences-granted

I think IHL has held up well in the last five weeks and I'll be keeping it on my watchlist as we head into the new year.

big.chart-IHL.gif
 
greggles said:
Just coming back to IHL around five weeks after my last post. After trading mostly between 2c and 3c since 24 October, IHL slipped below 2c last week on low volume. However, today saw it jump back over 2c on solid volume of around 12 million shares, up 29.41% on Friday's close.

I have read elsewhere that IHL are expecting that the licenses applied for last month (i.e. the importation, storage, distribution and export of medicinal cannabis products) are expected to be granted early next year.

Those interested in licenses being granted in this area can refer to this page: https://www.odc.gov.au/summary-licences-granted

I think IHL has held up well in the last five weeks and I'll be keeping it on my watchlist as we head into the new year.

View attachment 90521
Click to expand...


I have bought loads of these as it is substantially de-risked now following the granting of the cannabis import/export licence last week.

I went for the OBs though not the heads, the OBs at 0.005 - 0.006 are offering leverage of 3X-4X when compared to the heads.

A $50mn mkt cap would put the OBs on a ten bagger from current levels.

Most cannabis stocks are trading in the $100mn+ range which makes IHL's $10mn mkt cap look a extremely low in comparison especially when one factors in that IHL's dental supply business is already profitable.
 
Into a trading halt today, maybe the market will finally wake up to the fact that IHL is now a marijuana stock on the way up and will re-rate it accordingly when trading resumes.

Average peer group valuation is approx $90mn while IHL is still capped at a lowly $12mn leaving plenty of upside.
Let's see what the TH ANN contains.
 
Impression Healthcare teams up with Cannvalate in ‘first of its kind’ medical cannabis trial and distribution deal

Disruptive healthcare company Impression Healthcare (ASX: IHL) has teamed up with Australia’s largest network of medical cannabis clinics, Cannvalate, to distribute cannabinoid (CBD) medicines and undertake four clinical trials, including a “first of its kind” study on the effects of CBD oil on traumatic brain injury.


The company emerged from a trading halt this morning to announce the execution of a binding agreement, under which Cannvalate will purchase (on a wholesale basis) and distribute Impression’s licenced medical cannabis products throughout its huge network of more than 1,000 prescribing doctors and 600 pharmacies. More...
 
Impression Healthcare to supply concussion monitoring FitGuard mouthguard system

Impression Healthcare (ASX: IHL) has inked an exclusive agreement to supply the concussion monitoring FitGuard mouthguard system.


Under the agreement with Force Impact Technologies, Impression will sell the FitGuard technology suite including the FitGuard custom-fitted mouthguard, which measures cranial acceleration. The smart mouthguard has LEDs which display impact severity and Bluetooth connectivity to the FitApp.


The suite includes the app, which tracks impact history and provides athletes with cognitive performance exams. Meanwhile, the FitCloud stores data and can be used to model athlete performance.


As part of the exclusive distribution licence, Impression will arrange the mouthguards to be custom-fitted and distributed throughout Australia, New Zealand and Hong Kong.

“We are delighted to have cemented an exclusive supply agreement with Force over the FiTGuard system,” Impression chief executive officer Joel Latham. More...
 
On July 6th, 2020, Impression Healthcare Limited changed its name to Incannex Healthcare Limited.
 
Cannabinoid based pharmaceutical therapies are all the go now, IHL are well financed and focused on 4 liquid (mostly) CBD products.

Podcast presentation below.
~
 
Nice lift in share price today for IHL. Currently up 18.2% to 26c on volume of over 22 million shares after the company announced that its proprietary drug IHL-675A has been demonstrated to outperform CBD for anti-inflammatory properties in a pre-clinical in vivo study of inflammatory bowel disease.

IHL160221.png


Interestingly, the company has also said that the potent anti-inflammatory activity of IHL-675A in pulmonary conditions make it a good candidate for a multi-use medication. It could also be used to treat sepsis associated acute respiratory distress syndrome (‘SAARDS’), COPD, asthma and bronchitis.
 
greggles said:
Nice lift in share price today for IHL. Currently up 18.2% to 26c on volume of over 22 million shares after the company announced that its proprietary drug IHL-675A has been demonstrated to outperform CBD for anti-inflammatory properties in a pre-clinical in vivo study of inflammatory bowel disease.

View attachment 120159

Interestingly, the company has also said that the potent anti-inflammatory activity of IHL-675A in pulmonary conditions make it a good candidate for a multi-use medication. It could also be used to treat sepsis associated acute respiratory distress syndrome (‘SAARDS’), COPD, asthma and bronchitis.
Click to expand...
share price to stabilise for a while now and find a range?
 
needing to get money in the door, and doing it in two stages. These efforts usually suppress the SP.

Incannex Healthcare Limited (IHL), formerly Impression Healthcare Limited, is an innovator and developer of medicinal cannabinoid pharmaceutical products with global export capability.

Recent move ; Highlights:
  • Loyalty Options will be issued for nil consideration to Eligible Shareholders at a ratio of one (1) free Loyalty Option for every fifteen (15) shares held at 5:00 Australian Eastern Standard Time on the record date, 23 March 2022
  • Loyalty Options will have an exercise price of A$0.35, expiring 22 April 2022, and, if exercised, will result in the issue of a second Piggyback Option
  • Piggyback Options will be issued for nil consideration at a ratio of one (1) for every two (2) Loyalty Options exercised by the expiry date.
  • Piggyback Options will have an exercise price of A$1.00, expiring 28 April 2023
  • Loyalty Option and Piggyback Options are intended to reward loyal shareholders who have supported Incannex to its current stage of development and particularly after recent clinical trial success with IHL42X for Obstructive Sleep Apnoea
  • Option package facilitates additional funding from existing shareholders for extensive clinical trial endeavours ramping up in 2022 and 2023.
 
Top